The date format must match "dd.mm.YYYY"
This combination showed advantages in survival and recurrence. An added benefit was not proven for another combination used in advanced disease.
From January 2019, Jens Flintrop will be Head of the Communications Unit. After many years as a journal editor, he became press officer at the Westfalen-Lippe Association of SHI Physicians.
Following a negative G-BA decision due to a lack of data in 2013, the drug manufacturer now presented a suitable, albeit very short study.
For psoriasis, it has been known since 2007 that UV light therapy should be combined with brine baths. New data have now shown this also for atopic eczema.
Even eleven years after the first benefit assessment, the evidence base remains inadequate. The hopes to be able to close gaps in knowledge were disappointed when PREFERE failed in 2016 due to a lack of interest.
There are no suitable studies for the benefit assessment of screenings of the general population. Thorough accompanying evaluation is required for hepatitis C screening of risk groups.
About 1000 experts are expected to participate in the annual meeting of Health Technology Assessment International (HTAi) in Cologne. IQWiG is coordinating the scientific Programme.
The treatment effect on disease-free survival is not large enough to derive an effect on overall survival from it.
Compliance of pharma companies is relatively good, but very poor for university research groups. Research funders should make allocation of further funding dependent on data transparency.
Communicating evidence so that it reaches decision-makers, despite persistent prejudice and interest-driven interference: How does that work? We will discuss this on 23 and 24 November.
IQWiG still sees no basis for introducing a screening programme. There were neither comments on the preliminary report nor other new findings.
New guidelines change the results of the final report versus the preliminary report: Stronger focus, among other things, on the avoidance of hypoglycaemia by means of modern technologies.
TAILORx is the first available study with long-term follow-up suitable for the assessment. The Oncotype DX test apparently identifies women who can omit chemotherapy.
The treatment has been used in hospitals for over 20 years, and more than 100 studies have been completed worldwide. But manufacturers and researchers are concealing a large proportion of the results.
Less pain in stiff shoulders and improved mobility after total knee replacement – but the final report does not confirm greater benefit in rotator cuff tears.
In two early benefit assessments, IQWiG was unable to derive an added benefit from the data presented because current standards of care were not implemented in the studies.
NIPD can reduce the number of invasive tests and hence the number of test-related miscarriages in women whose foetuses are at an increased risk of trisomy 21.
IQWiG researchers involved in the early benefit assessment of palbociclib wrote a letter to the editor on the analysis of data from the PALOMA-2 study.
An update of the 2013 assessment shows that, due to a lack of suitable studies, data are missing for people with a family history of colorectal cancer.
The new non-invasive test, using a blood sample of the pregnant woman, is as reliable as the conventional test using a blood sample of the newborn. Studies on benefit and harm are still lacking.
+49 221 35685-151
Dr. Anna-Sabine Ernst
+49 221 35685-153
+49 221 35685-158
To save your search result, please copy the link below and paste it into a new tab/window.